Aktis Oncology (NASDAQ:AKTS) Stock Has Average Price Target of $35.62 According to Brokerages

Shares of Aktis Oncology (NASDAQ:AKTS) have earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $35.62.

A number of brokerages recently issued reports on AKTS. Raymond James Financial began coverage on Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. Oppenheimer initiated coverage on shares of Aktis Oncology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $40.00 target price for the company. Wedbush started coverage on shares of Aktis Oncology in a research note on Wednesday, August 19th. They issued an “outperform” rating and a $35.00 target price for the company. Wall Street Zen cut Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, JPMorgan Chase & Co. increased their target price on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th.

Insider Buying and Selling at Aktis Oncology

In other news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the sale, the director directly owned 3,506 shares in the company, valued at $86,107.36. This trade represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Aktis Oncology

Several large investors have recently modified their holdings of the stock. State of Wyoming acquired a new position in shares of Aktis Oncology in the 2nd quarter valued at about $32,000. AXQ Capital LP bought a new stake in Aktis Oncology during the 2nd quarter valued at $226,000. Susquehanna International Group LLP acquired a new stake in Aktis Oncology in the second quarter worth about $278,000. Deutsche Bank AG boosted its stake in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after purchasing an additional 6,942 shares in the last quarter. Finally, Readystate Asset Management LP bought a new stake in shares of Aktis Oncology in the 2nd quarter worth approximately $967,000. Institutional investors own 28.84% of the company’s stock.

Aktis Oncology Stock Performance

AKTS opened at $18.52 on Friday. Aktis Oncology has a one year low of $14.72 and a one year high of $34.19. The company has a market cap of $995.45 million and a P/E ratio of -22.59. The business’s 50-day simple moving average is $23.55 and its 200-day simple moving average is $22.17.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. As a group, analysts predict that Aktis Oncology will post -1.85 earnings per share for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biotechnology company focused on developing precision cancer treatments. The company’s research is centered on targeted alpha therapies, which are designed to deliver highly potent radiation directly to cancer cells while limiting exposure to surrounding healthy tissue.

Aktis Oncology is developing a pipeline of investigational therapies for solid tumors and other cancers. Its programs are intended to use tumor-targeting molecules to selectively transport radioactive payloads to cancer cells, with the goal of improving treatment effectiveness and addressing cancers that may be difficult to treat with conventional approaches.

The company’s product candidates remain in development and are subject to clinical, regulatory and commercial risks.